emerging glp-1 gip treatments 2025 Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research GLP1-GIP receptor co-agonists: a promising

MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy

These drugs are whats known as GLP-1s, just like Ozempic, the popular diabetes medication that kicked off a revolution in the pharmaceutical industry and inspired as many as 12% of people in the U.S

At Begin to Trim, we specialize in personalized GLP-1 weight loss programs that support your long-term wellness goals

However, it should not replace your sunscreen

That said, some patients report subjective increases in urination after starting therapy

This practice introduces cross-contamination and stability risks